Clinical Trial Update: Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of fulvestrant and abemaciclib in women with advanced low-grade serous ovarian carcinoma. The study is currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Carcinoma

Drugs mentioned

• Faslodex (fulvestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Female Genital Organs | Phase 2 | Status: ACTIVE_NOT_RECRUITING